Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy

Jingjing Wu, Peng Zhu, Zhanguo Zhang, Bixiang Zhang, Chang Shu, Lin Chen, Renjie Feng, Abdoul aziz Mba'nbo koumpa, Ganxun Li and Qianyun Ge
Cancer Biology & Medicine November 2018, 15 (4) 415-424; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0095
Jingjing Wu
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peng Zhu
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhupeng{at}tjh.tjmu.edu.cn bixiangzhang{at}163.com
Zhanguo Zhang
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bixiang Zhang
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zhupeng{at}tjh.tjmu.edu.cn bixiangzhang{at}163.com
Chang Shu
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Chen
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renjie Feng
2Department of Neurology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdoul aziz Mba'nbo koumpa
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganxun Li
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianyun Ge
1Department of Hepatic Surgery Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

Objective: Spontaneous hepatocellular carcinoma (HCC) rupture can be fatal, and hepatic resection could achieve a favorable long-term survival among all strategies of tumor rupture. However, there is no available prognostic scoring system for patients with ruptured HCC who underwent partial hepatectomy.

Methods: From January 2005 to May 2015, 129 patients with spontaneous HCC rupture underwent partial hepatectomy. Preoperative clinical data were collected and analyzed. Independent risk factors affecting overall survival (OS) were used to develop the new scoring system. Harrell’s C statistics, Akaike information criterion (AIC), the relative likelihood, and the log likelihood ratio were calculated to measure the homogeneity and discriminatory ability of a prognostic system.

Results: In the multivariable Cox regression analysis, three factors, including tumor size, preoperative α-fetoprotein level, and alkaline phosphatase level, were chosen for the new tumor-associated antigen (TAA) prognostic scoring system. The 1-year OS rates were 88.1%, 43.2%, and 30.2% for TAA scores of 0–5 points (low-risk group), 6–9 points (moderate-risk group), and 10–13 points (high-risk group), respectively. The TAA scoring system had superior homogeneity and discriminatory ability (Harrell’s C statistics, 0.693 vs. 0.627 and 0.634; AIC, 794.79 vs. 817.23 and 820.16; relative likelihood, both < 0.001; and log likelihood ratio, 45.21 vs. 22.77 and 21.84) than the Barcelona Clinic Liver Cancer staging system and the Cancer of the Liver Italian Program in predicting OS. Similar results were found while predicting disease-free survival (DFS).

Conclusions: The new prognostic scoring system is simple and effective in predicting both OS and DFS of patients with spontaneous ruptured HCC.

keywords

  • Spontaneous rupture
  • prognostic scoring system
  • homogeneity
  • discriminatory ability
  • overall survival
  • disease-free survival
  • hepatocellular carcinoma

Introduction

Spontaneous rupture of a tumor is considered fatal in patients with hepatocellular carcinoma (HCC), with a reported incidence rate ranging from 3% to 15%1-4. HCC ruptures may lead to dismal clinical outcomes, and mortality rates in the acute phase remain high5-8. The treatment and prognosis of ruptured HCC remain controversial as yet. Some treatment strategies have been reported, including supportive care, transcatheter arterial embolization (TAE), emergency liver resection, and staged hepatectomy1,4,5. Many studies have confirmed that surgical resection (whether emergency or staged) could achieve a better long-term survival than other treatments in selected patients and is a safe and effective therapy in hospital5,6,9-13.

However, given this condition’s rare occurrence, only a limited number of studies have been conducted to determine the prognostic factors for postoperative survival; to our knowledge, no postoperative prognostic model has been proposed. Therefore, a new prognostic scoring system for patients with ruptured HCC who underwent partial hepatectomy is needed.

The present study aimed to create and validate a new postoperative scoring system for patients with spontaneous HCC rupture based on the 10-year clinical data of a large single center. We also aimed to compare the discriminatory ability and homogeneity of the new model with the existing classification systems [Barcelona Clinic Liver Cancer (BCLC), the Cancer of the Liver Italian Program (CLIP), and the Okuda system].

Patients and methods

Patient selection

Between January 2005 and May 2015, 246 patients with complete data were diagnosed with spontaneous rupture of HCC at Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. Among them, 86 patients underwent non-surgical treatment (50 for transcatheter hepatic arterial embolization or transcatheter hepatic arterial chemoembolization and 36 for best supportive care), and 141 patients underwent surgical treatment ultimately. About 12 of the 141 patients underwent palliative surgery such as microwave coagulation therapy, ligation of the hepatic artery, or suturing ligation surgery instead of partial hepatectomy. A total of 129 patients were included in the analysis (Figure 1).

1
  • Download figure
  • Open in new tab
  • Download powerpoint
1

Study flowchart. TACE, transcatheter arterial chemoembolization; TAE, transcatheter arterial embolization.

Diagnosis, treatment, and follow-up

Normally, the diagnosis of HCC rupture was based on signs and symptoms upon admission, such as acute abdominal pain and shock, and confirmed by at least two of the following kinds of imaging examinations: abdominal ultrasonography (US), magnetic resonance imaging (MRI), and/or spiral computed tomography (CT) scanning. Diagnostic abdominal paracentesis was performed in patients without contraindications. Ultimately, hemorrhage was confirmed by surgical exploration. Routine pre-operation testing included a peripheral blood test; liver and kidney function checks; serum electrolyte, serum markers of hepatitis B and C viruses; and serologic α-fetoprotein (AFP) measurements; electrocardiography; coagulation function; and chest X-ray.

The primary goal of acute management was maintaining stable hemodynamics (to avoid hemorrhagic shock) by means of active vein fluid resuscitation, and blood products would be used if indicated. All hospitalized patients who had unstable hemodynamics were closely monitored in the intensive care unit or ward. Following the initial immediate treatment in most cases, bleeding could be controlled spontaneously. TAE was deemed an effective therapy in achieving hemostasis in patients without severely impaired liver function or other contraindications. Child-Pugh C grade was recognized as an absolute contraindication for both liver surgery and TAE. After TAE, partial hepatectomy was taken into account. Definitive treatment was based on tumor extent, the status of liver function, the general condition of the patient, and the treatment wishes of the patient and his or her family members.

Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue. All operative procedures were performed by experienced surgeons, and the abdominal cavity was extensively explored during the operation. During the resection, Pringle’s maneuver was applied when necessary to occlude the hepatic blood inflow. The desirable tumor margin during resection was more than 1 cm. Transection of liver parenchyma was traditionally implemented using the clamp-crushing technique or sometimes using a BiClamp or ultrasonic scalpel. Sutures and an argon beam coagulator were used for hemostasis. The degree and type of differentiation and cirrhosis were confirmed by postoperative pathological examination.

During the study period, various types of outpatient examinations, telephone interview, or re-admission were performed. The follow-up period ended on December 31, 2017, or when the patient died or was lost to follow-up. All patients were followed up once a month for 6 months after the operation and then every 3 months if there was no recurrence. Tests for complete blood count, liver and kidney function, coagulation function, and serum AFP level; abdominal ultrasonography; and chest X-ray were performed routinely after the operation. Digital subtraction angiography, abdominal CT or MRI, bone scan, chest CT, head CT, or positron emission tomography (PET) might be performed in patients with suspected relapse. The treatment recommendations in cases of tumor recurrence have been decided at a multidisciplinary liver tumor conference and include reoperation, percutaneous ablative therapy, percutaneous ethanol injection, transarterial chemoembolization (TACE), radiotherapy, intravenous chemotherapy, and sorafenib (since 2008) oral tablets. The treatment decision was usually made after a consultation with the patient and the family members. DFS was defined as the time interval from the date of surgery to recurrence or the latest follow-up if no evidence of recurrence was found. OS also was recorded. This study adhered to the ethical principles set by the Declaration of Helsinki.

Statistical analysis

The optimum cut-off value of alkaline phosphatase (ALP) was 100.5 U/L, based on the maximum sum of sensitivity and specificity of the ALP value for predicting OS in receiver operating characteristic curve analysis. Tumor size was divided into three levels using cut-off values of 5 and 10 cm. Likewise, AFP was divided based on the cut-off values of 20 and 400 ng/mL. All statistical analyses were conducted using SPSS 24.0 (IBM Corp., Armonk, NY, USA) and R software 3.4.3 for Windows (http://www.r-project.org), combined with other packages (Harrell Miscellaneous, survival, survminer, ggsurvplot, and ggpar). A two-sided P-value of < 0.05 was considered significant. Continuous data were summarized as mean ± standard deviation (SD) or median (range or quartile) for ordinal and non-normally distributed variables, respectively. Categorical data were expressed as number ( n) or proportion (%). Continuous data between groups were compared using Student’s t-test when it met the application conditions; otherwise, the Mann-Whitney U test was used. Categorical data were compared using χ2 test with (or without) the Yates correction or Fisher’s exact test, depending on the situation. Univariate survival analysis of OS and DFS was performed, and the results were compared using a log-rank test and presented with Kaplan-Meier curves. After initial univariate survival analysis, multivariate Cox survival analysis was carried out, and the hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated.

The results of regression coefficient ratios in the final Cox model for OS were obtained and rounded to the nearest whole number for further analysis. We received the final weights of each factor using this approach. After adding up the weights of all risk factors, the evaluation risk scores of tumor-associated antigen (TAA) were obtained. All cases were ultimately divided into three risk groups according to their TAA scores. The survival rate among the three risk groups was compared by log-rank test.

The patients were divided into risk groups based on the TAA scoring system (stages I, II, and III), BCLC staging system (stages A, B, and C), and CLIP classification. Homogeneity and discriminatory ability were observed to measure the performance of a classification system14,15. Harrell’s C statistics (C-index) was used to determine the discriminatory ability of the TAA scoring system, BCLC staging system, and CLIP classification system. The C-index ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination). A higher C-index implies superior discriminative ability in each prognostic system. Homogeneity was evaluated by the log likelihood ratio generated from the Cox proportional hazard model. A higher log likelihood ratio in the model suggests better homogeneity of postoperative survival of those patients in the same stage. In addition, the Akaike Information Criteria (AIC) was used to determine the discriminatory ability of a given prognostic model. A lower AIC indicates lower information loss of the model and better goodness of fit. The relative likelihood of models represents the probability that TAA minimizes information loss as effectively as BCLC (or CLIP) and can be interpreted succinctly as a P-value for the comparison of AIC differences. The relative likelihood of TAA vs. BCLC or CLIP model was calculated using the following formula: exp [(AICTAA/AICBCLC or CLIP)/2].

Results

Patient and tumor characteristics

All patients (113 men and 16 women) during the study period who underwent partial liver resection had a mean age of 46.3 ± 11.5 years. Table 1 summarizes patients’ demographic, clinical, and laboratory characteristics. Among them, 116 patients (83.5%) were HBsAg positive. The median size (maximum diameter) of the liver tumor was 70 mm (interquartile range, 50–100 mm), among which most were single tumors (n = 98, 76.0%). On admission, shock was present in 23 (17.7%) patients in our cohort. Further details could be found in Table 1.

View this table:
  • View inline
  • View popup
1

Demographic, clinical, and laboratory characteristics of patients with ruptured HCC who underwent partial liver resection

At the end of follow-up, 99 (70.7%) patients died, including 98 (69.7%) who died due to tumor-related or liver-related causes. Only 1 (1.0%) patient died due to myocardial infarction, and that was the only case of postoperative hospital death reported in this study. OS rates for 1, 2, 3, and 5 years were 53.5%, 37.2%, 30.8%, and 19.6%, respectively, and 1-, 2-, 3-, and 5-year DFS rates were 33.3%, 21.7%, 18.3%, and 10.7%, respectively.

Prognostic factors

Univariate survival analysis identified the following indexes associated with OS: tumor size, macroscopic vascular invasion, total bilirubin level, AFP level, ALP level, and blood transfusion in the hospital. In addition, aspartate aminotransferase factor level >40 U/L was a risk factor for poor DFS not OS ( Supplementary Table S1). Each variable with a P-value <0.05 in the univariate analysis was used in the multivariable model. Multivariable Cox regression showed that tumor size (T), AFP (A) and ALP (A) ( Supplementary Figure S1) were independent risk factors associated with OS. Similar results were also found for DFS (Table 2).

View this table:
  • View inline
  • View popup
S1

Univariate analysis of predictive factors associated with overall survival (OS) and disease-free survival (DFS)

Prognostic index

In Cox regression, the coefficients (β) and hazard ratio (HR) for each risk factor were reported in Table 2. In the final model, three factors for OS were adopted. The three prognostic factors were tumor size < 5 cm (weight, 0), 5–10 cm (weight, 4), or ≥ 10 cm (weight, 5); AFP ≤ 20 ng/mL (weight, 0), 20–400 ng/mL (weight, 3), or >400 ng/mL (weight, 5); and ALP >100.5 U/L (weight, 3) ( Table 3). Risk scores ranged from 0 to 13 points. All patients were grouped based on their risk scores; approximately 88.1% of patients with low risk (0–5 points, n = 42) survived more than 1 year, compared with 43.2% of those with moderate risk (6–9 points, n = 44) and 30.2% of those with high risk (10–13 points, n = 43). OS rates among different risk score groups classified based on the TAA scoring system were significantly different, as shown in Figure 2 (P < 0.001). OS rates for 2, 3, and 5 years were 73.8%, 64.1%, and 44.2%, respectively, in the low-risk group and 27.3%, 24.8%, and 15.5%, respectively, in the moderate-risk group. However, the OS rates were only 9.3%, 4.7%, and 0, respectively, in the high-risk group.

View this table:
  • View inline
  • View popup
2

Multivariate analysis of predictive factors associated with overall survival (OS) and disease-free survival (DFS)

View this table:
  • View inline
  • View popup
3

Components of the TAA risk scores

In addition, the difference in DFS was also highly significant in the new staging system (Supplementary Figure S2).

The CLIP and BCLC showed significant difference in terms of predicting both OS (Figure 2) and DFS (Supplementary Figure S2) (both P < 0.001). Unfortunately, no significant difference was found for Okuda system neither in OS ( Figure 2) (P = 0.678) nor in DFS (Supplementary Figure S2) (P = 0.074); thus, it was not included in the further analysis.

2
  • Download figure
  • Open in new tab
  • Download powerpoint
2

Overall survival predicted by TAA scoring systems (A), the Barcelona Clinic Liver Cancer (BCLC) classification systems (B), the Cancer of the Liver Italian Program (C), and the Okuda system (D). Differences were analyzed using the log-rank test.

S2
  • Download figure
  • Open in new tab
  • Download powerpoint
S2

Disease-free survival in different TAA scoring systems (A) and BCLC classification systems (B), CLIP system (C), and Okuda system (D). Differences were analyzed by the log-rank test for the significance of differences.

Model assessment

Homogeneity and discriminatory ability were evaluated by Harrell’s C statistics, AIC, and log likelihood ratio. The TAA scoring system showed a higher Harrell’s C statistic (0.693) compared with the traditional BCLC (0.627) and the CLIP (0.634) classification system. This result demonstrates that the discriminatory ability of the new TAA staging is better than the old ones. Similarly, the TAA scoring system had a lower AIC (794.79) compared with the BCLC (817.23) and the CLIP (820.16) classification system. Likewise, the TAA scoring system correlated with less information loss than both the BCLC and CLIP in predicting OS (both the relative likelihood < 0.001). Similar results were found for the log likelihood ratio (TAA to BCLC to CLIP, 45.21 : 22.77 : 21.81) ( Table 4). Thus, the TAA score system has better discriminatory ability and homogeneity for predicting OS than the BCLC classification system.

View this table:
  • View inline
  • View popup
4

Comparison of TAA, BCLC and CLIP prognostic scoring system in predicting overall survival (OS)

Furthermore, the new staging system showed higher homogeneity and discriminatory ability in predicting DFS (Supplementary Table S2).

View this table:
  • View inline
  • View popup
S2

Comparison of TAA, BCLC and CLIP prognostic scoring systems in predicting disease-free survival (DFS)

Hence, the TAA scoring system could be more informative than the Okuda, BCLC, and CLIP classification system for predicting survival.

Discussion

Spontaneous tumor rupture is uncommon but fatal in patients with HCC5,6. The mechanism of tumor rupture is still uncertain. Risk of tumor rupture was reported to associate with expanding growth tumor size, tumor necrosis, and hepatic vein obstruction by a tumor thrombus4,16-19. The leading cause of death after tumor rupture was either bleeding complications or hepatic failure in the short term20. Compared with TAE or conservative management alone, hepatic resection was reported to achieve a better in-hospital or 1-month survival. In addition, the cause of death was related to tumor-related events in the long-term survival, consisting of tumor recurrence or metastasis20. By contrast, surgical resection could achieve a more favorable long-term outcome20. Hence, partial hepatectomy would be the best treatment due to its effect on both short-term and long-term survival5,9-12,20.

In the current HCC staging systems, tumor rupture is arbitrarily classified as T4 disease regardless of other tumor or clinical index21-23, although this classification of ruptured HCC remains controversial because of its inability in reflecting a true prognosis accurately24. Thus, tumor node metastasis (TNM) staging systems are unavailable to reclassify HCC rupture. The Japan Integrated Staging score was based on the TNM staging and consequently, was not included in the analysis. The BCLC classification system25-28 could be used in patients with this type of disease, but the Eastern Cooperative Oncology Group performance scores may not be applicable to bed-bound patients. In our hepatic surgery center, about half of the patients with spontaneous ruptured HCC were treated with partial hepatectomy, and we consequently analyzed the postoperative risk factors of these 129 patients. Results showed that there is a significant relationship between the following factors: tumor size, AFP, ALP, and postoperative outcomes in patients with spontaneous ruptured HCC. Furthermore, we developed and validated a simple TAA scoring system that can effectively predict the OS and DFS of these patients.

In the present study, tumor size can be an independent risk factor for survival of patients with spontaneous ruptured HCC, and this finding is consistent with that reported in a previous large patient cohort study in China12. Tumor size was classified by the cut-off value of 5 and 10 cm in our study (median diameter of the tumor was 7.0 cm). To date, the largest proportion of patients with HCC rupture was the subject of a nationwide survey in Japan reported by Aoki et al.24 In this study, tumor size was considered as the main independent risk factor of survival, with the largest odds ratio. In addition, relatively high tension in large tumors suggested an association with the occurrence of spontaneous tumor rupture1. A study in China also suggested a link between tumor size ≥ 5 cm and high propensity for rupture29. In summary, large tumor size suggests not only a rupture tendency but also worse chance of survival. Furthermore, tumor size has been included in many prognostic evaluation systems for HCC, such as TNM, BCLC, Okuda, Chinese University Prognostic Index (CUPI), and CLIP21,25,30-32.

AFP, as a serum cancer marker, is used frequently for HCC diagnosis and prognosis prediction including CLIP and CUPI31-37. Levels of AFP were also reported as a survival risk factor in patients with spontaneous ruptured HCC12. This present study showed that AFP could predict overall survival and tumor recurrence. Occasionally, the sensitivity of AFP may be unsatisfactory for the detection of HCC37-39; however, in our study, ALP may have a prognostic role, even though serum AFP was negative (Supplementary Figure S1).

S1
  • Download figure
  • Open in new tab
  • Download powerpoint
S1

Overall survival (A) (C) (E) and disease-free survival (B) (D) (F) in all patients (A) (B). Patients were classified into an AFP-positive group (n = 94) (C) (D) and AFP-negative group (n = 35) (E) (F). Differences between different ALP groups were analyzed using the log-rank test for the significance of differences.

ALP, not a tissue-specific marker, can exist in all tissues and organs of the body. As the cause of liver damage and cholestasis, an elevated ALP level can be found in some hepatobiliary disease, such as primary biliary cirrhosis, cholangitis, choledocholithiasis, hepatitis40-43. The common ground of all these diseases is inflammation, which could play a role in tumor formation. Meanwhile, ALP was observed to have prognostic value for tumors such as HCC44 and cholangiocarcinoma45. Moreover, it has been used in prognostic scoring systems for HCC (CUPI)31 and intrahepatic cholangiocarcinoma46. Furthermore, ALP can affect tumor proliferation by undergoing nucleolar localization, as observed under an electron microscope47. In a cancer cell line such as Hep-G2, ALP was found to participate in cell cycles47. In general, ALP participates in tumor formation and represents inflammation reactions in various ways. In patients with ruptured HCC, the state of stress, blood loss, complex tumor status, poor liver function, and the worse general situation may suggest a more obvious inflammatory condition that may contribute to tumor formation. However, further research is needed to explore the mechanism underlying this.

This study showed that ALP has a predictive role for the survival of patients with spontaneous ruptured HCC who underwent partial hepatectomy. ALP is an easily accessible and relatively inexpensive laboratory index after admission. As a liver function parameter, ALP level can be a predictor of both OS and DFS independently after adjusting for other factors in the multivariate analysis.

Based on these three factors, we developed a new prognostic scoring system (TAA). The optimal prognostic classification system should have the maximal discriminatory ability to predict survival outcomes of different stages of ruptured HCC while keeping the variability of survival outcomes for each stage of the classification system to a minimum. The BCLC staging system, as a commonly accepted clinical classification, has provided recommended treatment strategies for different stages of HCC accordingly. Unfortunately, tumor rupture, a complication of HCC that requires urgent care, has not been fully considered in the BCLC staging system. This might be one of the possible reasons that the BCLC classification system did not display superior homogeneity and discriminatory ability in our study.

This research was implemented in one of the largest liver surgery centers in China; moreover, all surgeons had several years of practical experience in liver resection as treatment for hepatic tumors. When patients were diagnosed with HCC rupture, partial hepatectomy was first considered after admission. Partial hepatectomy would be performed when the patient met the application conditions. In our study, the proportion of patients with HCC rupture who underwent hepatic resection was 52.4% (129 of 246), which was higher than those reported in previous studies4,5,12,48.

This study had a few limitations. First, because of the retrospective nature of this study, its inherent shortcomings are unavoidable. Second, as a relatively rare disease, only a limited number of patients with HCC rupture underwent partial hepatectomy. Thus, only fewer patients were available for further analysis. Finally, owing to a larger proportion of hepatitis B virus-related HCC patients in this study, the patients’ clinical features may differ from those in Western countries.

Acknowledgements

We thank Professor Xiaoping Chen for patient management, Ms. Hongping Luo for patient care, and Dr. Hua Xiao, Ms. Jingjing Yu, and Miss Huiyuan Yang for patient register and follow-up.

Footnotes

  • Conflict of interest statement No potential conflicts of interest are disclosed.

  • Received May 9, 2018.
  • Accepted September 7, 2018.
  • Copyright: © 2018, Cancer Biology & Medicine
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    1. Zhu LX,
    2. Wang GS,
    3. Fan ST.
    Spontaneous rupture of hepatocellular carcinoma. Br J Surg. 1996; 83: 602–7.
    OpenUrlPubMed
  2. 2.↵
    1. Leung KL,
    2. Lau WY,
    3. Lai PBS,
    4. Yiu RYC,
    5. Meng WCS,
    6. Leow CK.
    Spontaneous rupture of hepatocellular carcinoma: conservative management and selective intervention. Arch Surg. 1999; 134: 1103–7.
    OpenUrlCrossRefPubMed
  3. 3.
    1. Nagasue N,
    2. Inokuchi K.
    Spontaneous and traumatic rupture of hepatoma. Br J Surg. 1979; 66: 248–50.
    OpenUrlPubMed
  4. 4.↵
    1. Lai ECH,
    2. Lau WY.
    Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg. 2006; 141: 191–8.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Liu CL,
    2. Fan ST,
    3. Lo CM,
    4. Tso WK,
    5. Poon RTP,
    6. Lam CM, et al.
    Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol. 2001; 19: 3725–32.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Cherqui D,
    2. Panis Y,
    3. Rotman N,
    4. Fagniez PL.
    Emergency liver resection for spontaneous rupture of hepatocellular carcinoma complicating cirrhosis. Br J Surg. 1993; 80: 747–9.
    OpenUrlPubMed
  7. 7.
    1. Xu HS,
    2. Yan JB.
    Conservative management of spontaneous ruptured hepatocellular carcinoma. Am Surg. 1994; 60: 629–33.
    OpenUrlPubMed
  8. 8.↵
    1. Chen CY,
    2. Lin XZ,
    3. Shin JS,
    4. Lin CY,
    5. Leow TC,
    6. Chen CY, et al.
    Spontaneous rupture of hepatocellular carcinoma. A review of 141 taiwanese cases and comparison with nonrupture cases. J Clin Gastroenterol. 1995; 21: 238–42.
    OpenUrl
  9. 9.↵
    1. Shimada R,
    2. Imamura H,
    3. Makuuchi M,
    4. Soeda J,
    5. Kobayashi A,
    6. Noike T, et al.
    Staged hepatectomy after emergency transcatheter arterial embolization for ruptured hepatocellular carcinoma. Surgery. 1998; 124: 526–35.
    OpenUrlPubMed
  10. 10.
    1. Liu H,
    2. Peng YH,
    3. Fu Y,
    4. Li RF.
    One-stage liver resection for spontaneous rupture of hepatocellular carcinoma. World J Surg. 2005; 29: 1316–8.
    OpenUrlPubMed
  11. 11.
    1. Vergara V,
    2. Muratore A,
    3. Bouzari H,
    4. Polastri R,
    5. Ferrero A,
    6. Galatola G, et al.
    Spontaneous rupture of hepatocelluar carcinoma: surgical resection and long-term survival. Eur J Surg Oncol. 2000; 26: 770–2.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Yang T,
    2. Sun YF,
    3. Zhang J,
    4. Lau WY,
    5. Lai ECH,
    6. Lu JH, et al.
    Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg. 2013; 100: 1071–9.
    OpenUrl
  13. 13.↵
    1. Yeh CN,
    2. Lee WC,
    3. Jeng LB,
    4. Chen MF,
    5. Yu MC.
    Spontaneous tumour rupture and prognosis in patients with hepatocellular carcinoma. Br J Surg. 2002; 89: 1125–9.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ueno S,
    2. Tanabe G,
    3. Sako K,
    4. Hiwaki T,
    5. Hokotate H,
    6. Fukukura Y, et al.
    Discrimination value of the new western prognostic system (clip score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology. 2001; 34: 529–34.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Marrero JA,
    2. Fontana RJ,
    3. Barrat A,
    4. Askari F,
    5. Conjeevaram HS,
    6. Su GL, et al.
    Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41: 707–15.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ong GB,
    2. Taw JL.
    Spontaneous rupture of hepatocellular carcinoma. Br Med J. 1972; 4: 146–9.
    OpenUrlAbstract/FREE Full Text
  17. 17.
    1. Kew MC,
    2. Dos Santos HA,
    3. Sherlock S.
    Diagnosis of primary cancer of the liver. Br Med J. 1971; 4: 408–11.
    OpenUrlAbstract/FREE Full Text
  18. 18.
    1. Alpert ME,
    2. Hutt MSR,
    3. Davidson CS.
    Primary hepatoma in uganda: a prospective clinical and epidemiologic study of forty-six patients. Am J Med. 1969; 46: 794–802.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Hermann RE,
    2. David TE.
    Spontaneous rupture of the liver caused by hepatomas. Surgery. 1973; 74: 715–9.
    OpenUrlPubMed
  20. 20.↵
    1. Moris D,
    2. Chakedis J,
    3. Sun SH,
    4. Spolverato G,
    5. Tsilimigras DI,
    6. Ntanasis-Stathopoulos I, et al.
    Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol. 2018; 117: 341–53.
    OpenUrl
  21. 21.↵
    1. Amin MB,
    2. Edge SB,
    3. Greene FL,
    4. Byrd DR,
    5. Brookland RK,
    6. Washington MK, et al.
    AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
  22. 22.
    1. Chun YS,
    2. Pawlik TM,
    3. Vauthey JN.
    8th edition of the ajcc cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018; 25: 845–7.
    OpenUrl
  23. 23.↵
    1. Subramaniam S,
    2. Kelley RK,
    3. Venook AP.
    A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013; 2: 33.
    OpenUrl
  24. 24.↵
    1. Aoki T,
    2. Kokudo N,
    3. Matsuyama Y,
    4. Izumi N,
    5. Ichida T,
    6. Kudo M, et al.
    Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg. 2014; 259: 532–42.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Llovet JM,
    2. Brú C,
    3. Bruix J.
    Prognosis of hepatocellular carcinoma: the bclc staging classification. Semin Liver Dis. 1999; 19: 329–38.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Llovet JM,
    2. Burroughs A,
    3. Bruix J.
    Hepatocellular carcinoma. Lancet. 2003; 362: 1907–17.
    OpenUrlCrossRefPubMed
  27. 27.
    1. Forner A,
    2. Llovet JM,
    3. Bruix J.
    Hepatocellular carcinoma. Lancet. 2012; 379: 1245–55.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Forner A,
    2. Reig M,
    3. Bruix J.
    Hepatocellular carcinoma. Lancet. 2018; 391: 1301–14.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Zhu Q,
    2. Li J,
    3. Yan JJ,
    4. Huang L,
    5. Wu MC,
    6. Yan YQ.
    Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol. 2012; 18: 7302–7.
    OpenUrlPubMed
  30. 30.↵
    1. Okuda K,
    2. Ohtsuki T,
    3. Obata H,
    4. Tomimatsu M,
    5. Okazaki N,
    6. Hasegawa H, et al.
    Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985; 56: 918–28.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Leung TWT,
    2. Tang AMY,
    3. Zee B,
    4. Lau WY,
    5. Lai PBS,
    6. Leung KL, et al.
    Construction of the chinese university prognostic index for hepatocellular carcinoma and comparison with the tnm staging system, the okuda staging system, and the cancer of the liver italian program staging system. Cancer. 2002; 94: 1760–9.
    OpenUrlCrossRefPubMed
  32. 32.↵
    The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the clip score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000; 31: 840–5.
    OpenUrlCrossRefPubMed
  33. 33.
    1. Collier J,
    2. Sherman M.
    Screening for hepatocellular carcinoma. Hepatology. 1998; 27: 273–8.
    OpenUrlCrossRefPubMed
  34. 34.
    1. Daniele B,
    2. Bencivenga A,
    3. Megna AS,
    4. Tinessa V.
    α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004; 127: S108–12.
    OpenUrlCrossRefPubMed
  35. 35.
    1. Blank S,
    2. Wang Q,
    3. Fiel MI,
    4. Luan W,
    5. Kim KW,
    6. Kadri H, et al.
    Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis b-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol. 2014; 21: 986–94.
    OpenUrl
  36. 36.
    1. Llovet JM,
    2. Peña CEA,
    3. Lathia CD,
    4. Shan M,
    5. Meinhardt G,
    6. Bruix J.
    Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290–300.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Silva JP,
    2. Gorman RA,
    3. Berger NG,
    4. Tsai S,
    5. Christians KK,
    6. Clarke CN, et al.
    The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. J Surg Oncol. 2017; 116: 831–40.
    OpenUrl
  38. 38.
    1. Spangenberg HC,
    2. Thimme R,
    3. Blum HE.
    Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006; 26: 385–90.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Bertino G,
    2. Ardiri A,
    3. Malaguarnera M,
    4. Malaguarnera G,
    5. Bertino N,
    6. Calvagno GS.
    Hepatocellualar carcinoma serum markers. Semin Oncol. 2012; 39: 410–33.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Lu LG,
    2. Zeng MD,
    3. Wan MB,
    4. Li CZ,
    5. Mao YM,
    6. Li JQ, et al.
    Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol. 2003; 9: 2574–8.
    OpenUrlPubMed
  41. 41.
    1. Lammers WJ,
    2. van Buuren HR,
    3. Hirschfield GM,
    4. Janssen HLA,
    5. Invernizzi P,
    6. Mason AL, et al.
    Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014:1338–1349.e5.
  42. 42.
    1. LaRusso NF,
    2. Shneider BL,
    3. Black D,
    4. Gores GJ,
    5. James SP,
    6. Doo E, et al.
    Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006; 44: 746–64.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Padda MS,
    2. Singh S,
    3. Tang SJ,
    4. Rockey DC.
    Liver test patterns in patients with acute calculous cholecystitis and/or choledocholithiasis. Aliment Pharmacol Ther. 2009; 29: 1011–8.
    OpenUrlPubMed
  44. 44.↵
    1. Yeh CN,
    2. Chen MF,
    3. Lee WC,
    4. Jeng LB.
    Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol. 2002; 81: 195–202.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Bhudhisawasdi V,
    2. Muisuk K,
    3. Areejitranusorn P,
    4. Kularbkaew C,
    5. Khampitak T,
    6. Saeseow OT, et al.
    Clinical value of biliary alkaline phosphatase in non-jaundiced cholangiocarcinoma. J Cancer Res Clin Oncol. 2004; 130: 87–92.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Jiang W,
    2. Zeng ZC,
    3. Tang ZY,
    4. Fan J,
    5. Sun HC,
    6. Zhou J, et al.
    A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the fudan score. Ann Oncol. 2011; 22: 1644–52.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Yamamoto K,
    2. Awogi T,
    3. Okuyama K,
    4. Takahashi N.
    Nuclear localization of alkaline phosphatase in cultured human cancer cells. Med Electron Microsc. 2003; 36: 47–51.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Miyamoto M,
    2. Sudo T,
    3. Kuyama T.
    Spontaneous rupture of hepatocellular carcinoma: a review of 172 japanese cases. Am J Gastroenterol. 1991; 86: 67–71.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 15 (4)
Cancer Biology & Medicine
Vol. 15, Issue 4
1 Nov 2018
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy
Jingjing Wu, Peng Zhu, Zhanguo Zhang, Bixiang Zhang, Chang Shu, Lin Chen, Renjie Feng, Abdoul aziz Mba'nbo koumpa, Ganxun Li, Qianyun Ge
Cancer Biology & Medicine Nov 2018, 15 (4) 415-424; DOI: 10.20892/j.issn.2095-3941.2018.0095

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy
Jingjing Wu, Peng Zhu, Zhanguo Zhang, Bixiang Zhang, Chang Shu, Lin Chen, Renjie Feng, Abdoul aziz Mba'nbo koumpa, Ganxun Li, Qianyun Ge
Cancer Biology & Medicine Nov 2018, 15 (4) 415-424; DOI: 10.20892/j.issn.2095-3941.2018.0095
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Machine learning-based clinical decision support tool for advanced ESCC in the immunotherapy era: a multi-center study
  • Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors
  • Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter study
Show more Original Article

Similar Articles

Keywords

  • Spontaneous rupture
  • prognostic scoring system
  • homogeneity
  • discriminatory ability
  • overall survival
  • disease-free survival
  • Hepatocellular carcinoma

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire